Trimebutine
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Trimebutine: From Gastrointestinal Motility Disorder to Migraine Disorder
One-Sentence Summary
Trimebutine is a peripheral opioid receptor agonist historically used for gastrointestinal motility disorders (e.g., IBS, functional dyspepsia), though this evidence pack does not confirm its original approved indication. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 4 publications (including 1 RCT) currently supporting this direction — largely as an absorption-enhancing adjunct to triptans rather than a primary antimigraine agent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (data gap); pharmacologically consistent with GI motility disorders based on mechanism description |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L2 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap). Based on the repurposing rationale provided, Trimebutine is a peripheral opioid receptor agonist (mu/kappa/delta) with spasmolytic and prokinetic action on gastrointestinal smooth muscle, acting mainly on the Meissner and Auerbach plexuses without CNS penetration.
The link to migraine is not a direct antimigraine mechanism. During migraine attacks, gastroparesis commonly delays gastric emptying, which in turn delays absorption and onset of oral triptans. The proposed mechanism is that Trimebutine improves gastric emptying, thereby enhancing the bioavailability and clinical effect of co-administered oral triptans (e.g., rizatriptan) — an absorption-enhancement effect rather than a primary analgesic or antimigraine action.
Because original indication and MOA data are both marked as Data Gaps in this pack, this mechanistic reasoning is inferred primarily from literature titles/abstracts and known pharmacological classification, and should be treated as a hypothesis pending confirmation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16776704 | 2006 | RCT | Cephalalgia | Double-blind, randomized, cross-over, placebo-controlled study comparing rizatriptan alone vs. rizatriptan + trimebutine for acute migraine treatment; rationale based on trimebutine’s gastrokinetic effect counteracting migraine-associated gastroparesis to improve triptan absorption |
| 19220673 | 2009 | Review | Journal of Gastroenterology and Hepatology | Review of prokinetic agents’ effectiveness against diseases external to the GI tract, including CNS, respiratory, urologic, and metabolic conditions |
| 17046449 | 2006 | Review | Lancet | Review discussing strategies to increase the effect of triptans in migraine treatment (no abstract available) |
| 16245431 | 2005 | Case Report | Polski Merkuriusz Lekarski | Case report of abdominal migraine in a 9-year-old girl; trimebutine mentioned among prior unsuccessful treatments for functional abdominal pain (not migraine-specific efficacy evidence) |
India Market Information
Currently not marketed in India; no registration records are available in this evidence pack (total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/label warnings and contraindications data are flagged as a Blocking severity data gap (DG001) in this evidence pack, meaning safety pre-screening (S1) cannot currently be completed.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single small double-blind crossover RCT plus supporting reviews, with no registered clinical trials directly testing trimebutine for migraine; more importantly, a Blocking data gap on TFDA safety warnings/contraindications prevents the mandatory safety pre-screening step, and the drug is not currently marketed in India.
To proceed, the following is needed:
- TFDA/label warnings, contraindications, and DDI data (DG001, Blocking — required before safety review)
- Confirmed original approved indication(s) and mechanism of action (DG002, High)
- Dedicated clinical trials evaluating trimebutine’s effect on migraine outcomes (not solely as a triptan-absorption adjunct)
- Clarification of India market entry pathway, given current “Not Marketed” status and zero registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.